ES2057339T3 - Medicamento para la aplicacion por via subcutanea o intramuscular que contiene polipeptidos. - Google Patents

Medicamento para la aplicacion por via subcutanea o intramuscular que contiene polipeptidos.

Info

Publication number
ES2057339T3
ES2057339T3 ES90122730T ES90122730T ES2057339T3 ES 2057339 T3 ES2057339 T3 ES 2057339T3 ES 90122730 T ES90122730 T ES 90122730T ES 90122730 T ES90122730 T ES 90122730T ES 2057339 T3 ES2057339 T3 ES 2057339T3
Authority
ES
Spain
Prior art keywords
subcutaneous
medication
application
containing polypeptides
intramuscular route
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90122730T
Other languages
English (en)
Inventor
Eric-Paul Dr Paques
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siemens Healthcare Diagnostics GmbH Germany
Original Assignee
Behringwerke AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6394356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2057339(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Behringwerke AG filed Critical Behringwerke AG
Application granted granted Critical
Publication of ES2057339T3 publication Critical patent/ES2057339T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A61K38/58—Protease inhibitors from animals; from humans from leeches, e.g. hirudin, eglin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

SE PRESENTA UN MEDICAMENTO LIQUIDO PARA APLICACIONES SUBCUTANEAS O INTRAMUSCULARES CONTENIENDO UN POLIPEPTIDO Y AL MENOS UN AMINOACIDO, UN PROCEDIMIENTO PARA LA FABRICACION DE UN MEDICAMENTO DE ESTE TIPO ASI COMO LA UTILIZACION DE UN AMINOACIDO EN UNA SOLUCION DE UN POLIPEPTIDO QUE SEA ADECUADO EN UTILIZACION SUBCUTANEA O INTRAMUSCULAR.
ES90122730T 1989-11-29 1990-11-28 Medicamento para la aplicacion por via subcutanea o intramuscular que contiene polipeptidos. Expired - Lifetime ES2057339T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3939346A DE3939346A1 (de) 1989-11-29 1989-11-29 Arzneimitel zur subkutanen oder intramuskulaeren applikation enthaltend polypeptide

Publications (1)

Publication Number Publication Date
ES2057339T3 true ES2057339T3 (es) 1994-10-16

Family

ID=6394356

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90122730T Expired - Lifetime ES2057339T3 (es) 1989-11-29 1990-11-28 Medicamento para la aplicacion por via subcutanea o intramuscular que contiene polipeptidos.

Country Status (12)

Country Link
US (1) US5691312A (es)
EP (1) EP0430200B1 (es)
JP (1) JP3143470B2 (es)
KR (1) KR910009246A (es)
AT (1) ATE106746T1 (es)
AU (1) AU657466B2 (es)
CA (1) CA2030988C (es)
DE (2) DE3939346A1 (es)
DK (1) DK0430200T3 (es)
ES (1) ES2057339T3 (es)
IE (1) IE64080B1 (es)
PT (1) PT96016B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364839A (en) * 1990-06-18 1994-11-15 Genetics Institute, Inc. Osteoinductive pharmaceutical formulations
DE4126984A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, gut vertraeglichen arzneimitteln fuer infusions- oder injektionszwecke
SE9300105D0 (sv) * 1993-01-15 1993-01-15 Kabi Pharmacia Ab Stable protein solution
EP0803255A4 (en) * 1994-06-03 1999-06-30 Tsumura & Co DRUG
US5770700A (en) * 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
TWI240627B (en) * 1996-04-26 2005-10-01 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
HU224222B1 (hu) * 1996-12-24 2005-06-28 Biogen Inc. Stabil folyékony interferon-készítményformák és eljárás interferon stabilizálására
DE10149030A1 (de) * 2001-10-05 2003-04-10 Viscum Ag Stabile galenische gefriergetrocknete Arzneimittelzubereitung von rViscumin
AU2002351756A1 (en) 2001-12-21 2003-07-15 Novo Nordisk Health Care Ag Liquid composition of factor vii polypeptides
AU2003219958B2 (en) * 2002-02-27 2006-01-05 Immunex Corporation Polypeptide formulation
AU2003240438A1 (en) 2002-06-21 2004-01-06 Novo Nordisk A/S Stabilised solid compositions of factor vii polypeptides
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
EP1628677B1 (en) 2003-05-23 2010-01-13 Novo Nordisk Health Care AG Protein stabilization in solution
KR101293503B1 (ko) 2003-08-14 2013-08-07 노보 노르디스크 헬스 케어 악티엔게젤샤프트 인자 ｖｉｉ 폴리펩티드의 액상 수성 약학적 조성물
PL2298287T3 (pl) 2003-12-19 2019-02-28 Novo Nordisk Health Care Ag Stabilizowane kompozycje polipeptydów czynnika VII
CA2610839C (en) 2005-06-14 2019-06-25 Amgen Inc. Self-buffering protein formulations
WO2007146945A2 (en) * 2006-06-12 2007-12-21 Aspen Aerogels, Inc. Aerogel-foam composites
WO2009130181A2 (en) * 2008-04-21 2009-10-29 Novo Nordisk Health Care Ag Dry transglutaminase composition
WO2013082418A1 (en) 2011-11-30 2013-06-06 3M Innovative Properties Company Microneedle device having a peptide therapeutic agent and an amino acid, methods of making and using the same
EP4039253A1 (en) 2015-04-29 2022-08-10 Radius Pharmaceuticals, Inc. Methods of treating cancer
MX2019004580A (es) 2016-10-21 2019-08-12 Amgen Inc Formulaciones farmaceuticas y metodos para prepararlas.
KR20230109795A (ko) 2017-01-05 2023-07-20 래디어스 파마슈티컬스, 인코포레이티드 Rad1901-2hcl의 다형 형태
SG11202013177WA (en) 2018-07-04 2021-01-28 Radius Pharmaceuticals Inc Polymorphic forms of rad 1901-2hcl

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56135418A (en) * 1980-03-27 1981-10-22 Green Cross Corp:The Heat treatment of aqueous solution containing 8 factor of coagulation of blood derived from human
US4508709A (en) * 1983-12-05 1985-04-02 Armour Pharmaceutical Company Process for purifying factor VIII:C
EP0156169B1 (en) * 1984-02-29 1991-12-18 Asahi Kasei Kogyo Kabushiki Kaisha An aqueous solution of a tissue plasminogen activator dissolved therein at an increased concentration and a method
US4656034A (en) * 1985-05-20 1987-04-07 Survival Technology, Inc. Absorption enhancing agents
JPS6197229A (ja) * 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
US4839170A (en) * 1985-10-01 1989-06-13 Survival Technology, Inc. Protein absorption enhancing agents
DE3625090A1 (de) * 1986-07-24 1988-01-28 Behringwerke Ag Mittel zur therapie faktor viii-resistenter haemophilie a und verfahren zu seiner herstellung
DE3643182A1 (de) * 1986-12-18 1988-06-30 Behringwerke Ag Arzneimittel enthaltend das gewebeprotein pp4, verfahren zur herstellung von pp4 und zu seiner pasteurisierung sowie die verwendung von pp4
US4857320A (en) * 1987-02-19 1989-08-15 Monsanto Company Method of enhancing the solubility of tissue plasminogen activator
DE3729863A1 (de) * 1987-09-05 1989-03-16 Boehringer Mannheim Gmbh Stabilisierte erythropoietin-lyophilisate
DE3718889A1 (de) * 1987-06-05 1988-12-22 Behringwerke Ag Verfahren zur herstellung einer loesung hoher spezifischer volumenaktivitaet von einem protein mit gewebe-plasminogenaktivator (t-pa)-aktivitaet, loesung, enthaltend protein mit t-pa-aktivitaet und verwendung der loesung in der human- und veterinaermedizin
JP2708749B2 (ja) * 1987-08-10 1998-02-04 エーザイ株式会社 修飾型ｔＰＡ含有注射用組成物
DE4126983A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
US5358708A (en) * 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations

Also Published As

Publication number Publication date
DE59006032D1 (de) 1994-07-14
JPH03170437A (ja) 1991-07-24
EP0430200A1 (de) 1991-06-05
ATE106746T1 (de) 1994-06-15
PT96016A (pt) 1991-09-13
AU657466B2 (en) 1995-03-16
DK0430200T3 (da) 1994-09-26
AU6702990A (en) 1991-06-06
DE3939346A1 (de) 1991-06-06
CA2030988A1 (en) 1991-05-30
US5691312A (en) 1997-11-25
KR910009246A (ko) 1991-06-28
EP0430200B1 (de) 1994-06-08
CA2030988C (en) 2004-11-16
IE64080B1 (en) 1995-07-12
JP3143470B2 (ja) 2001-03-07
IE904292A1 (en) 1991-06-05
PT96016B (pt) 1998-06-30

Similar Documents

Publication Publication Date Title
ES2057339T3 (es) Medicamento para la aplicacion por via subcutanea o intramuscular que contiene polipeptidos.
ES2039283T3 (es) Solucion para dialisis y utilizacion de peptidos a base de glicina para su preparacion.
MX168523B (es) Sistemas indicadores de tiempo de duracion y productos que los contienen y tienen duracion limitada de uso de vida
DE3785207T2 (de) Pumpvorrichtung zur abgabe von fluessigkeit bei hohem druck.
DE3577039D1 (de) Fingerbetaetigtes infusionssystem zur medikamentoesen versorgung.
DE68909691T2 (de) Multischichtkörper zur Abgabe von Duftstoffen.
DE3586713D1 (de) Vorrichtung zur kontrollierten abgabe von arzneimittelwirkstoffen.
ES2041832T3 (es) Dispositivos para contacto,durante el uso, con un flujo de sangre.
BR9710452A (pt) Anïïlogos de exendina processos para sua prepara-Æo e medicamentos contendo os mesmos
DE3789320D1 (de) Verabreichungsinstrument zum Einführen von festen Medikamenten.
DE68913970T2 (de) Schimärische peptide für die lieferung von neuropeptiden durch die blut-hirn-barriere.
ES2114183T3 (es) Anticuerpo para el tratamiento de la diabetes dependiente de la insulina.
FI864760A (fi) Ihmiskehoon istutettava keinotekoinen rauhanen
ES2062073T3 (es) Composiciones de tinta que contiene una mezcla de un poliester, un polimero acrilico y un polimero vinilico.
ES2080800T3 (es) Polipeptidos y analogos de polipeptidos con actividad inhibitoria frente a la elastasa humana.
ES2045868T3 (es) Dispositivo para la preparacion de disoluciones de uso medico.
ATE72963T1 (de) Konditionierfluessigkeiten von zahn- oder knochensubstanz.
ES2134189T3 (es) Procedimiento para la preparacion de un producto de celulosa oxidado neutralizado y uso del mismo.
DE69001991D1 (de) Fluessige arzneimittel zur nasalen anwendung, die ein polypeptid als wirksubstanz enthalten.
DE301974T1 (de) Kartusche zur injektion der mischung von zwei fluessigkeitskomponenten.
DE3871477D1 (de) Behaelter zur aufnahme verbrauchter injektionsnadeln.
ES2062649T3 (es) Pigmentos de vanadato de bismuto, procedimientos para su fabricacion asi como su uso.
ES2027232T3 (es) Botella para mezclar y metodo para mezclar con dicha botella.
DE3687245D1 (de) Thermotrope cholesterinische fluessigkristalle bildende polypeptide.
DE68910973D1 (de) Arzneimittelzusammensetzung, enthaltend deoxyribonukleoside für heilung von wunden.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 430200

Country of ref document: ES